Pipeline Analysis of Galectin 1 Therapeutic Assessment Covering Drug Profiles Reviewed in H2 2017

Market Research Hub (MRH) has freshly announced the inclusion of a new study to its wide research database, which is titled as “Galectin 1 - Pipeline Review, H2 2017”. The study provides a comprehensive information on the global therapeutic landscape for Galectin 1 with relative analysis at various stages which include drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The research study of 63 pages, built using proprietary databases along with latest updatesand featured news & press releases from various university sites and industry specific third party sources.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1256899

The report begins with the detailed introduction of Galectin 1, which is a soluble carbohydrate binding protein with distinct functions. It is encoded by the LGALS1 gene. It plays an important role in regulating apoptosis, cell proliferation and cell differentiation. As per the findings, Gal-1 in its oxidized form plays a number of important roles in the regeneration of the central nervous system after injury. Galectins contain either one or two carbohydrate recognition domains (CRR) which mediate recognition of N-acetyl-lactosamine-containing glycoproteins. Additionally, it inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. It is a strong inducer of T-cell apoptosis.

It has been analyzed that, the targeted inhibition of Gal-1 expression is what should be developed for therapeutic applications against cancer progression. Gal-1 is thus a promising molecular target for the development of new and original therapeutic tools. This report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Immunology, Dermatology, Genetic Disorders, Genito Urinary System and Sex Hormones, Metabolic Disorders and Respiratory.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/galectin-1-14-kda-laminin-binding-protein-report.html

Further, pipeline guide also features descriptive drug profiles for the pipeline elements containing product description, descriptive licensing and collaboration details along with R&D and other developmental activities. The guide also covers the pipeline products that are based on numerous stages of development ranging from pre-registration till discovery and undisclosed stages. Some of the drugs profiled in the study are CNC-225, CNC-225 + CNC-118 + Anti-CTLA-4, Fusion Protein to Activate Gal-1 for Immunology, GMCT-01, GMRD-02, Monoclonal Antibody to Inhibit Galectin-1 for B-Cell Non-Hodgkin Lymphoma.

Furthermore, this report also reviews key players involved in Galectin 1 targeted therapeutics development with respective active and inactive or discontinued projects. They are Galectin Therapeutics Inc and GlycoMimetics Inc. With the above information, the buyer can gain benefits and improve tactical initiatives by understanding the focus areas of leading companies.

Enquire About this Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1256899

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street, 
Albany, NY 12207, 
United States

Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074 
Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.